White House keeps fo­cus on low­er­ing drug prices, turns Re­gen­eron's con­tract lan­guage in­to new stan­dard

As Pres­i­dent Joe Biden strug­gles in the most re­cent 2024 gen­er­al elec­tion polls, the White House is keep­ing its fo­cus on drug prices, go­ing af­ter phar­ma for the sec­ond time in as many weeks, with plans to find new ways to in­ter­act with in­dus­try on the fed­er­al gov­ern­ment’s terms.

While the plan to “march-in” on drug patents from last week will like­ly have on­ly a lim­it­ed ef­fect on a small sub­set of drugs, the ad­min­is­tra­tion on Thurs­day re­ferred to its pro­pos­al as putting “drug com­pa­nies on no­tice if prod­ucts de­vel­oped us­ing fed­er­al funds are not made avail­able to the pub­lic on rea­son­able terms, in­clud­ing based on price.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER